Baricitinib in two paediatric patients with coatomer subunit alpha (COPA) syndrome: A case series and literature review
Modern Rheumatology Case Reports · 29.06.2026 · 10 (2)
DOI: 10.1093/mrcr/rxag052 ↗Kurz gefasst
Fallbericht in der Zeitschrift Modern Rheumatology Case Reports, online erschienen am 24.06.2026. Verfasst von Enrique G Villarreal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada. Hauptthemen laut MEDLINE: Azetidines, Sulfonamides, Lung Diseases, Interstitial, Janus Kinase Inhibitors. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Coatomer subunit α (COPA) syndrome is a rare, autosomal dominant inborn error of immunity driven by dysregulated type I interferon signalling. It typically presents in early childhood with interstitial lung disease, arthritis, and systemic inflammation. Current treatments are largely extrapolated from adult protocols, and disease management remains challenging. Recent evidence suggests that Janus kinase inhibitors (JAKi), which block interferon signalling, may offer a targeted therapeutic approach. We report on two paediatric patients with genetically confirmed COPA syndrome who demonstrated sustained clinical improvement following the initiation of baricitinib, a JAKi. Both cases exhibited early onset interstitial lung disease and systemic inflammation. Genetic testing identified pathogenic variants in the COPA gene. Conventional immunosuppressants provided only partial and temporary relief with disease flares occurring when immunosuppression was tapered. Baricitinib was initiated, and both patients showed a rapid clinical response, improved pulmonary function, reduced systemic inflammation, lung parenchymal radiographic stabilisation, and improvement of interstitial lung disease symptoms. Baricitinib was well tolerated overall and enabled the tapering and discontinuation of corticosteroids and other immunosuppressants. These cases align with the limited existing literature showing the efficacy of JAKi in COPA syndrome and further support the role of precision medicine targeting type I interferonopathies. While long-term safety data remain limited, early findings suggest that JAK inhibition represents a promising therapeutic strategy in COPA syndrome. Careful monitoring for viral reactivation and infection is essential. Larger studies and longer follow-up are needed to validate these results and to optimise the management of this complex paediatric autoimmune disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatrics, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
- Division of Respiratory Medicine, The Hospital for Sick Children, Toronto, Canada.
- Division of Rheumatology, The Hospital for Sick Children, Toronto, Canada.
- Cell and Systems Biology Program, SickKids Research Institute, Toronto, Canada.
- Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
- Department of Cell and Systems Biology, University of Toronto, Toronto, Canada.
ORCID-Profile: Enrique G Villarreal, Dilan Dissanayake, Ronald M Laxer, Kenneth W Yip, Fiona Kritzinger
Zitieren
APA
Villarreal, E. G., Dissanayake, D., Laxer, R. M., Yip, K. W., & Kritzinger, F. (2026). Baricitinib in two paediatric patients with coatomer subunit alpha (COPA) syndrome: A case series and literature review. Modern Rheumatology Case Reports, 10(2). https://doi.org/10.1093/mrcr/rxag052
Vancouver
Villarreal EG, Dissanayake D, Laxer RM, Yip KW, Kritzinger F. Baricitinib in two paediatric patients with coatomer subunit alpha (COPA) syndrome: A case series and literature review. Modern Rheumatology Case Reports. 2026;10(2). doi:10.1093/mrcr/rxag052
BibTeX
@article{Villarreal2026,
author = {Villarreal, Enrique G and Dissanayake, Dilan and Laxer, Ronald M and Yip, Kenneth W and Kritzinger, Fiona},
title = {Baricitinib in two paediatric patients with coatomer subunit alpha (COPA) syndrome: A case series and literature review},
journal = {Modern Rheumatology Case Reports},
year = {2026},
volume = {10},
number = {2},
doi = {10.1093/mrcr/rxag052}
}
EUVIMED